{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T15:32:44Z","timestamp":1783524764047,"version":"3.55.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T00:00:00Z","timestamp":1719878400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T00:00:00Z","timestamp":1719878400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This retrospective cohort study investigated patients with cytomegalovirus anterior uveitis (CMV AU) and compared treatment outcomes between regional and systemic antiviral therapies. Treatment modalities included topical (2% ganciclovir [GCV] eye drops or 0.2% GCV eye gel) and systemic (intravenous GCV or oral valganciclovir) groups. The comparison parameters included response rates, time to response, recurrence rates, time to recurrence, and complications. Forty-four patients (54.5% male) with a mean age of 56\u2009\u00b1\u20099.87\u00a0years were enrolled, with 31 eyes in the topical group and 13 eyes in the systemic group. The median response time was significantly slower in the topical group (63\u00a0days [IQR 28\u2013112]) compared to the systemic group (28\u00a0days [IQR 24\u201359]) (<jats:italic>p<\/jats:italic>\u2009=\u20090.04). Treatment response rates were 87.1% (27\/31) in the topical group and 100% (13\/13) in the systemic group (<jats:italic>p<\/jats:italic>\u2009=\u20090.30), while recurrence rates were 37% (10\/27) and 69.2% (9\/13) (<jats:italic>p<\/jats:italic>\u2009=\u20090.056), with a median time to recurrence of 483\u00a0days [IQR 145\u20131388] and 392\u00a0days [IQR 203.5\u20131907.5] (<jats:italic>p<\/jats:italic>\u2009=\u20090.20), respectively. In conclusion, both topical and systemic GCV treatments demonstrated favorable outcomes for CMV AU. Systemic GCV showed rapid control of intraocular inflammation.<\/jats:p>","DOI":"10.1038\/s41598-024-66224-5","type":"journal-article","created":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T16:02:19Z","timestamp":1719936139000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Treatment outcomes in cytomegalovirus anterior uveitis"],"prefix":"10.1038","volume":"14","author":[{"given":"Thanut","family":"Boonhaijaroen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pitipol","family":"Choopong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usanee","family":"Tungsattayathitthan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nattaporn","family":"Tesavibul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilawan","family":"Sanphan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sutasinee","family":"Boonsopon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,2]]},"reference":[{"issue":"1","key":"66224_CR1","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1080\/09273948.2017.1394471","volume":"26","author":"NS Chan","year":"2018","unstructured":"Chan, N. S., Chee, S. P., Caspers, L. & Bodaghi, B. Clinical features of CMV-associated anterior uveitis. Ocul. Immunol. Inflamm. 26(1), 107\u2013115 (2018).","journal-title":"Ocul. Immunol. Inflamm."},{"issue":"1","key":"66224_CR2","doi-asserted-by":"publisher","first-page":"185","DOI":"10.3390\/v15010185","volume":"15","author":"J Zhang","year":"2023","unstructured":"Zhang, J., Kamoi, K., Zong, Y., Yang, M. & Ohno-Matsui, K. Cytomegalovirus anterior uveitis: Clinical manifestations, diagnosis, treatment, and immunological mechanisms. Viruses 15(1), 185 (2023).","journal-title":"Viruses"},{"issue":"1","key":"66224_CR3","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1136\/bjophthalmol-2013-304625","volume":"99","author":"N Koizumi","year":"2015","unstructured":"Koizumi, N. et al. Clinical features and management of cytomegalovirus corneal endotheliitis: Analysis of 106 cases from the Japan corneal endotheliitis study. Br. J. Ophthalmol. 99(1), 54\u201358 (2015).","journal-title":"Br. J. Ophthalmol."},{"key":"66224_CR4","unstructured":"Maxwell Elia, M., John, J. H., Paul, A. & Gaudio, M.D. Cytomegalovirus anterior uveitis in immunocompetent patients. Ophthalmic pearls (2016)"},{"issue":"12","key":"66224_CR5","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1136\/bjo.2009.167767","volume":"94","author":"SP Chee","year":"2010","unstructured":"Chee, S. P. & Jap, A. Cytomegalovirus anterior uveitis: Outcome of treatment. Br. J. Ophthalmol. 94(12), 1648\u20131652 (2010).","journal-title":"Br. J. Ophthalmol."},{"issue":"1","key":"66224_CR6","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12348-016-0078-z","volume":"6","author":"JX Wong","year":"2016","unstructured":"Wong, J. X., Agrawal, R., Wong, E. P. & Teoh, S. C. Efficacy and safety of topical ganciclovir in the management of cytomegalovirus (CMV)-related anterior uveitis. J. Ophthalmic. Inflamm. Infect. 6(1), 10 (2016).","journal-title":"J. Ophthalmic. Inflamm. Infect."},{"issue":"1","key":"66224_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/bmjophth-2016-000061","volume":"2","author":"N Keorochana","year":"2017","unstructured":"Keorochana, N. & Choontanom, R. Efficacy and safety of an extemporaneous preparation of 2% ganciclovir eye drops in CMV anterior uveitis. BMJ Open Ophthalmol. 2(1), e000061 (2017).","journal-title":"BMJ Open Ophthalmol."},{"issue":"11","key":"66224_CR8","first-page":"833","volume":"54","author":"RY Zhai","year":"2018","unstructured":"Zhai, R. Y., Xu, H., Kong, X. M. & Wang, Z. J. Effect of 2% ganciclovir eye drops on cytomegalovirus positive Posner\u2013Schlossman syndrome. Zhonghua Yan Ke Za Zhi 54(11), 833\u2013838 (2018).","journal-title":"Zhonghua Yan Ke Za Zhi"},{"issue":"3","key":"66224_CR9","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","volume":"140","author":"DA Jabs","year":"2005","unstructured":"Jabs, D. A., Nussenblatt, R. B. & Rosenbaum, J. T. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am. J. Ophthalmol. 140(3), 509\u2013516 (2005).","journal-title":"Am. J. Ophthalmol."},{"issue":"11","key":"66224_CR10","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1007\/s00417-014-2782-4","volume":"252","author":"M Accorinti","year":"2014","unstructured":"Accorinti, M. et al. Cytomegalovirus anterior uveitis: long-term follow-up of immunocompetent patients. Graefes Arch. Clin. Exp. Ophthalmol. 252(11), 1817\u20131824 (2014).","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"issue":"1","key":"66224_CR11","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/s41433-023-02631-8","volume":"38","author":"ZX Thng","year":"2024","unstructured":"Thng, Z. X. et al. The infectious uveitis treatment algorithm network (TITAN) report 2-global current practice patterns for the management of Cytomegalovirus anterior uveitis. Eye (Lond.) 38(1), 68\u201375 (2024).","journal-title":"Eye (Lond.)"},{"key":"66224_CR12","doi-asserted-by":"publisher","first-page":"1321116","DOI":"10.3389\/fmicb.2023.1321116","volume":"14","author":"C Gourin","year":"2023","unstructured":"Gourin, C., Alain, S. & Hantz, S. Anti-CMV therapy, what next? A systematic review. Front. Microbiol. 14, 1321116 (2023).","journal-title":"Front. Microbiol."},{"key":"66224_CR13","doi-asserted-by":"publisher","first-page":"3395","DOI":"10.2147\/IDR.S370905","volume":"15","author":"PJ Chen","year":"2022","unstructured":"Chen, P. J. et al. Long-term outcome of treatment with 2% topical ganciclovir solution in cytomegalovirus anterior uveitis and corneal endotheliitis. Infect. Drug Resist. 15, 3395\u20133403 (2022).","journal-title":"Infect. Drug Resist."},{"key":"66224_CR14","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.2147\/OPTH.S376039","volume":"16","author":"K Mori","year":"2022","unstructured":"Mori, K. et al. Clinical features of glaucoma associated with cytomegalovirus corneal endotheliitis. Clin. Ophthalmol. 16, 2705\u20132711 (2022).","journal-title":"Clin. Ophthalmol."},{"key":"66224_CR15","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.ajo.2018.07.021","volume":"194","author":"S Touhami","year":"2018","unstructured":"Touhami, S. et al. Cytomegalovirus anterior uveitis: clinical characteristics and long-term outcomes in a French series. Am. J. Ophthalmol. 194, 134\u2013142 (2018).","journal-title":"Am. J. Ophthalmol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-66224-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-66224-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-66224-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T16:10:41Z","timestamp":1719936641000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-66224-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,2]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["66224"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-66224-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,2]]},"assertion":[{"value":"10 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15210"}}